bexobrutideg
Small molecule
Also known as RG7473
Evidence outlook · registrational
Relapsed/Refractory Chronic Lymphocytic Leukemia: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2029-10.
Also in development:Chronic Lymphocytic Leukemia · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07516093 NCT07516093 · Relapsed/Refractory Chronic Lymphocytic Leukemia Registry: NCT07516093 | 3 | Progression-free survival (PFS) as assessed by Independent Review Committee (IRC) (Up to approximately 3.5 years); Objective response rate (ORR) without partial response with lymphocytosis (PR-L) as assessed by IRC (Up to approximately 2.5 years) 2029-10 | In progress: results expected 1 Oct 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Bruton's tyrosine kinase (BTK) drugs
remibrutinib, Tolebrutinib, Corubrutinib. Compare all 4 Bruton's tyrosine kinase (BTK) drugs
3 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Chronic Lymphocytic Leukemia: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Bexobrutideg: this drug | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded | No reviewed efficacy summary in this indication | |
| Acalabrutinib | Approved | Small molecule | BTK | Partial signal | Featured results are non-efficacy only in this race | |
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | not yet graded | No reviewed efficacy summary in this indication | |
| Ibrutinib | Approved | Small molecule | BTK | Partial signal | NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62) | |
| Obinutuzumab | Approved | Monoclonal antibody | CD20 | Partial signal | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Pirtobrutinib | Approved | Small molecule | BTK | Partial signal | Featured results are non-efficacy only in this race | |
| Remibrutinib | Approved(overall) | Small molecule | Bruton's tyrosine kinase (BTK) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Rituximab (Rituxan) | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | not yet graded | No reviewed efficacy summary in this indication | |
| Rituximab-Abbs (Truxima) | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Venetoclax | Approved | Small molecule | BCL-2 | Partial signal | NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001) | |
| Zanubrutinib (Brukinsa) | Approved | Small molecule | BTK | Partial signal | NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results). | |
| Nemtabrutinib | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Sonrotoclax (Beqalzi) | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tolebrutinib | Phase 3(overall) | Small molecule | Bruton's tyrosine kinase (BTK) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Mesutoclax | Phase 2/3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Corubrutinib | Phase 2(overall) | Small molecule | Bruton's tyrosine kinase (BTK) | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| MS-553 | Phase 1/2 | Small molecule | Protein kinase C-beta (PKC-beta) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow bexobrutideg to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.